Leerink Partners Downgrades Agios Pharmaceuticals to Market Perform, Lowers Price Target to $56
Portfolio Pulse from Benzinga Newsdesk
Leerink Partners has downgraded Agios Pharmaceuticals from Outperform to Market Perform and reduced its price target from $60 to $56.
September 27, 2024 | 11:29 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Leerink Partners has downgraded Agios Pharmaceuticals from Outperform to Market Perform, reducing the price target from $60 to $56. This suggests a less optimistic outlook on the company's stock performance.
The downgrade from Outperform to Market Perform by Leerink Partners indicates a less favorable view on Agios Pharmaceuticals' stock, which could lead to a negative short-term impact on its stock price. The lowered price target further supports this outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100